On June 20, the South Korean biotechnology company Bridge Biotherapeutics, Inc. saw its stock price rise by 20.59%, with a market capitalization reaching 49.218 billion won, approximately 36 million USD. Previously, the investment company Parataxis Holdings, which focused on the digital asset sector, announced that it had signed a final agreement with the biotechnology company Bridge Biotherapeutics, Inc. to invest 25 billion won, thereby acquiring a controlling stake in the company ("this transaction"). After the transaction is completed, the company plans to change its name to Parataxis Korea and continue to be listed on KOSDAQ.